Cell-Free Protein Expression: An Introduction to TXTL Systems

Cell-free expression systems like myTXTL combined with high-fidelity gene fragments enable rapid protein production from DNA within hours rather than days, eliminating traditional cloning and cell culture steps; this approach allows researchers to screen protein libraries, analyze metabolic pathways, and test gene circuits efficiently by directly synthesizing proteins in an open reaction environment without requiring living cells.

Combining machine learning with ultra-high-throughput screening enables more effective protein optimization than traditional directed evolution methods, as demonstrated by achieving a 19-fold improvement in nuclease activity compared to 12-fold improvement from directed evolution after three rounds of optimization, along with greater diversity in the designed enzyme variants.

The All-E. coli TXTL system can express up to 4 mg/mL GFP in batch mode without feeding, reaching 150-160 micromolar concentration. Expression kinetics show protein accumulation followed by plateau at chemical equilibrium. The system recapitulates the entire sigma factor transcription scheme from E. coli, with all sigma factors specific to their promoters. Performance has improved dramatically: Toolbox 1 (2012) achieved ~1 mg/mL GFP, Toolbox 2 (2016) ~2 mg/mL, and Toolbox 3 ~4 mg/mL. For T7 phage expression, improvement from 10^8 to 10^14 PFU represents a 1000-fold increase. TXTL systems can be developed from various bacteria including Gram-positive and Gram-negative species from Proteobacteria, Actinobacteria, and Firmicutes. Using fluorescent aptamers and next-generation sequencing, researchers can characterize hundreds to 1000 different regulatory elements in a single tube. CRISPR technology works effectively in TXTL for prototyping, allowing determination of on-off ratios of guide RNAs at any location on target genes. TXTL can express very large gene sets including entire phage genomes: MS2 (small RNA phage), 5x174 (11 kb), T7 phage (40 kb, 60 genes), and T4 phage (169 kb, almost 300 genes).

Cell-free transcription-translation (TXTL) systems enable protein synthesis outside living cells by providing purified cellular machinery including transcription and translation components, ATP regeneration systems, amino acids, and cofactors. The workflow involves preparing DNA templates and mixing them with reaction components, then incubating for several hours to produce proteins. TXTL enables three main applications: prototyping gene circuits and pathways, biomanufacturing proteins and viral particles, and creating synthetic cells. Advanced applications include synthesizing complete viral genomes (up to 289 genes for T4 phage), engineering phage genomes through in vitro assembly and selection, and developing synthetic cells using liquid-liquid phase separation or liposome encapsulation. Microfluidic chips enable spatial organization of gene circuits for studying pattern formation and communication between neighboring cells. This technology accelerates genetic circuit design, enables rapid prototyping of CRISPR components, and provides a platform for exploring synthetic biology without requiring living host cells.

Wild-type enzymes have varying characteristics (temperature tolerance, solvent resistance, activity levels) that may not suit industrial processes. Enzyme engineering modifies DNA sequences to change amino acid order, defining protein shape, activity, and stability. Two approaches exist: random mutation (screening many variants for improved activity) and rational design (using structural knowledge to target specific amino acids). Directed evolution mimics natural evolution: mutations are created, enzymes are produced and tested, and beneficial mutations are selected for further rounds. High-throughput screening is essential due to the large number of mutants required. Cell-free systems and microfluidics enable rapid screening of thousands of enzyme mutants by encapsulating enzymes in oil droplets at micrometer scale, allowing reactions to be monitored and active droplets sorted electronically.

Non-canonical fluorescent amino acids like ANAP can be incorporated into proteins using amber suppression techniques. This involves co-expressing a tRNA synthetase that recognizes amber codons (UAG) and the target protein with an amber codon. The technique allows site-specific incorporation of non-canonical amino acids at defined positions within the protein structure. This method has been adapted for use in Xenopus oocytes and other cell types, enabling researchers to place fluorescent probes at specific locations within membrane proteins like H+ channels. The technique provides a powerful tool for studying protein structure and function at the molecular level.

Non-standard amino acids include selenocysteine and pyrrolysine, which are incorporated into proteins during translation through unique mechanisms. Selenocysteine is encoded by the UGA stop codon and contains selenium instead of sulfur. Pyrrolysine is encoded by the UAG stop codon and is found in certain methanogenic archaea. These amino acids require specific tRNA and release factors for incorporation. Additionally, beta and gamma amino acids have the amino group attached to the beta or gamma carbon respectively, rather than the alpha carbon. These non-standard amino acids expand the chemical diversity of proteins beyond the 20 standard amino acids.

This section establishes the foundational concepts of incorporating non-natural amino acids into proteins. Three primary approaches exist: total chemical synthesis (limited to 30-50 residues), native chemical ligation (forming traceless amide bonds via thioester exchange), and post-translational modifications. Biological methods offer advantages for longer proteins and site-specific placement. The core challenge is creating a placeholder codon and attaching non-natural amino acids to tRNAs. Nonsense suppression using stop codons as placeholders was pioneered by Bailey and Schultz, involving chemically aminoacylated suppressor tRNAs. In vitro methods use translation mixtures, while in vivo approaches inject mRNA and tRNAs into Xenopus oocytes. Key limitations include restriction to L-alpha amino acids, tRNA as limiting reagent, and competition between termination and suppression at stop codons.

While 20 amino acids are sufficient for most proteins, nature sometimes uses extra chemical diversity through vitamins and other molecules. Scientists can incorporate non-natural amino acids into proteins to add new chemical properties and functions. This expands the possibilities for protein engineering beyond the natural 20 amino acids.

Beyond the 20 canonical amino acids, chemists have access to thousands of potential non-canonical amino acid chemistries with diverse properties. These building blocks offer features not available through natural amino acids, including novel catalytic activities for bond formation and reactions that are orthogonal (independent) to nature's evolved life processes. This expansion opens possibilities for creating proteins with entirely new functions and properties.

Cell-free biosensing uses lysed bacterial extracts containing transcription and translation machinery to detect biomarkers. This platform addresses limitations of traditional clinical testing by enabling finger-stick blood collection, low-cost assays (pennies per test), and deployment in resource-limited settings without electricity or specialized equipment. Polymer-based two-phase systems (dextran/PEG) enable compartmentalization of reactions into separate droplets, allowing simultaneous detection of nucleic acids, proteins, and small molecules from the same sample. Freeze-dried colorimetric reporters (X-gal/lacZ) provide visually interpretable readouts suitable for point-of-care applications.

DARPA initiated a program to develop on-demand therapeutic manufacturing for forward-deployed medical providers, requiring: generic platform capable of producing diverse protein therapeutics, portability allowing production within 24 hours, complete end-to-end manufacturing chain including purification, and production of FDA-approved biologics with consistency matching hospital-grade injectables. Cell-based systems were deemed impractical due to minimum 24-hour timelines. Conventional manufacturing involves complex multi-stage processes: master cell bank storage, cell expansion through multiple stages, large-scale reactor cultivation, recovery/purification steps, stabilization, formulation, and shipping. The proposed paradigm shift moves manufacturing to the point of care using compact modular systems. Cell-free IVT systems eliminate living cells and cold chain requirements, enabling raw materials to be stored lyophilized and reconstituted on demand. Early studies produced FDA-approved therapeutics like arthropoietin at single-band purity in less than two days, and streptokinase with high potency. Producing single-dose biologics requires manufacturing conditions with precision comparable to electronics manufacturing. Generic purification strategies use inteins—self-cleaving polypeptide sequences that respond to pH or temperature switches to release pure tagless protein.

Cell-free protein expression is a powerful biotechnology that extracts cellular machinery (transcription and translation enzymes) from living cells to synthesize proteins in vitro, offering advantages over traditional cell-based methods including faster workflow, elimination of transformation steps, and the ability to produce toxic or difficult-to-express proteins; this technology has three main applications: protein production for research and therapeutics, functional genomics studies to understand biological systems, and point-of-care diagnostics where freeze-dried cell-free systems can be embedded in paper or pellets for portable, decentralized healthcare applications.

Cell-free synthetic biology enables the creation of stable, portable diagnostic platforms by freeze-drying biological components onto paper, allowing rapid detection of pathogens (such as Ebola, Zika, antibiotic-resistant bacteria, HPV, and cancer-related biomarkers) without requiring living cells, specialized equipment, or refrigeration, with detection limits reaching femtomolar concentrations and costs as low as two cents per test.

This technology enables on-demand manufacturing of protein-based drugs by freeze-drying cellular machinery that can produce therapeutic molecules when activated with water, allowing for compact, room-temperature storage of drug production capabilities rather than pre-made drugs, with potential applications in disaster areas and remote locations.